Products of the company cover a wide range of areas, including ELISA, Dot ELISA, colloidal gold tests, molecular, vaccines, and quality control products. The company has achieved a 100% market share in provincial blood centers and a nearly 100% coverage rate among biological product companies. It has successfully developed and launched the world's first intranasal COVID-19 vaccine. As a core production base for HIV diagnostic reagents in the Asia-Pacific region and a national demonstration base for the industrialization of biological high-tech, Beijing Wantai is committed to being an innovator in the vaccine field and safeguarding public health.